xmab20717
mAbexperimentalMulti-specific
Clinical trial activity
9 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Jul 10, 2018 (NCT03517488)
Timeline
Indications
Studied for
- Adenocarcinoma, Clear Cell · Phase 2
- Basal Cell Carcinoma · Phase 1
- Biliary Tract Neoplasms · Phase 2
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Neuroendocrine · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Cholangiocarcinoma · Phase 1
- Colonic Neoplasms · Phase 2
- Colorectal Neoplasms · Phase 2
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Hodgkin Disease · Phase 2
- Melanoma · Phase 1
- Mesothelioma · Phase 2
- Nasopharyngeal Carcinoma · Phase 1
- Neoplasms · Phase 2
- Neoplasms, Adnexal and Skin Appendage · Phase 1
- Ovarian Neoplasms · Phase 2
- Peritoneal Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 1
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Rectal Neoplasms · Phase 2
- Salivary Gland Neoplasms · Phase 1
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Thymoma · Phase 1
- Thyroid Neoplasms · Phase 2
- Tuberculosis, Extrapulmonary · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Vulvar Neoplasms · Phase 1
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
- Cytotoxic T-lymphocyte protein 4INHIBITOR
CTLA4 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594617 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05900648 | Phase 2 | Nov 30, 2024 | Bayer, University of Texas at Houston, Xencor |
| NCT06173505 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2023 | Xencor |
| NCT05733351 | Phase 1 | Aug 3, 2023 | Emory University, National Cancer Institute (NCI), Xencor |
| NCT05337735 | Phase 2 | Aug 5, 2022 | University of Texas at Houston |
| NCT05453799 | Phase 2 | Jul 21, 2022 | National Cancer Institute (NCI), Northwestern University |
| NCT05297903 | Phase 2 | Apr 11, 2022 | University of Pennsylvania, Xencor |
| NCT05032040 | Phase 2 | Dec 31, 2021 | ICON, Xencor |
| NCT05005728 | Phase 2 | Oct 22, 2021 | Xencor |
| NCT03517488 | Phase 1 | Jul 10, 2018 | ICON, Xencor |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xencor | For profit | 7 | 4 | 2 | 2018 |
| ICON | For profit | 2 | 0 | 2 | 2018 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2022 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 1 | 2022 |
| Bayer | For profit | 1 | 0 | 1 | 2024 |
| Emory University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2022 |
8 organizations
Page 1 / 1